Drug Search Results
More Filters [+]

Ridaforolimus

Alternative Names: ridaforolimus, mk-8669, ap23573, mk8669
Latest Update: 2024-06-11
Latest Update Note: News Article

Product Description

Mechanisms of Action: mTOR Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Merck
Company Location: KENILWORTH NJ 07033
Company CEO: Robert M. Davis
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Ridaforolimus

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 3: Sarcoma|Osteosarcoma|Bone Cancer|Soft Tissue Cancer

Phase 2: Myeloid Leukemia|Myelodysplastic Syndrome|Lymphoma|Myelofibrosis|Prostate Cancer|Sarcoma|Oncology Unspecified|Liposarcoma|Leiomyosarcoma|Osteosarcoma|Endometrial Cancer|Non-Small-Cell Lung Cancer|Breast Cancer

Phase 1: Non-Small-Cell Lung Cancer|Sarcoma|Heart Cancer|Ovarian Cancer|Glioblastoma|Lymphoma|Breast Cancer|Oncology Unspecified|Endometrial Cancer|Multiple Myeloma|Oncology Solid Tumor Unspecified|Glioma|Gliosarcoma|Prostate Cancer|Colorectal Cancer|Primary Central Nervous System Lymphoma|Hepatic Insufficiency|Fallopian Tube Cancer|Liver Failure|Peritoneal Cancer

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

IoNIR-002

N/A

Not yet recruiting

Coronary Artery Disease|Coronary Stenosis

2025-09-01

CHAMPIONSHIP

N/A

Not yet recruiting

Peripheral Arterial Disease

2025-08-30

IonMAN

N/A

Recruiting

Non-ST Elevated Myocardial Infarction|Coronary Stenosis|Coronary Disease

2023-12-01

EluNIR-005

N/A

Completed

Coronary Stenosis|Myocardial Ischemia

2021-11-02

Recent News Events